
Request Information
Learn more
This website contains promotional content and is intended for Healthcare Professionals based in the United States only.



.jpg)
Factor VIII (FVIII) replacement therapies have been a step forward for the prevention and treatment of bleeding episodes in patients with hemophilia A. One remaining challenge is the development of neutralizing antibodies, known as inhibitors, which interfere with patient response to a factor infusion or render it ineffective.
MAT-US-2405607-v1.0-06/2024